B

Biovaxys Technology Corp
CNSX:BIOV

Watchlist Manager
Biovaxys Technology Corp
CNSX:BIOV
Watchlist
Price: 0.19 CAD -5% Market Closed
Market Cap: 8.1m CAD

Biovaxys Technology Corp
Total Other Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Biovaxys Technology Corp
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
B
Biovaxys Technology Corp
CNSX:BIOV
Total Other Income
CA$1.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abcellera Biologics Inc
NASDAQ:ABCL
Total Other Income
$58.5m
CAGR 3-Years
50%
CAGR 5-Years
101%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Total Other Income
$29k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Willow Biosciences Inc
TSX:WLLW
Total Other Income
-CA$767k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
NervGen Pharma Corp
XTSX:NGEN
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biovaxys Technology Corp
Glance View

Market Cap
8.1m CAD
Industry
N/A

BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-11-21. The firm is focused on developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is using its haptenized antigen technology platforms to develop vaccines to treat viral infections, such as SARS-CoV-2, human papillomavirus (HPV) and cancers, such as late-stage ovarian cancer, cervical cancer and melanoma. Its product portfolio includes BVX-0320, BVX-0121, BVX-0204, BVX-0918A, BVX-0918C, CoviDTH and Papilocare. BVX-0320 is an investigational new drug (IND)-stage vaccine candidate for SARS-CoV-2. The vaccine is the recombinant S1 subunit of the spike protein of SARS-CoV-2 that has been modified with a chemical called hapten, specifically, dinitrophenyl (DNP). Its CoviDTH is a disposable, diagnostic tool to identify a T-cell immune response to the presence of SARS-CoV-2. BVX-0918A is a haptenized tumor cell vaccine for ovarian cancer.

BIOV Intrinsic Value
0.003 CAD
Overvaluation 98%
Intrinsic Value
Price
B

See Also

What is Biovaxys Technology Corp's Total Other Income?
Total Other Income
1.1m CAD

Based on the financial report for Oct 31, 2024, Biovaxys Technology Corp's Total Other Income amounts to 1.1m CAD.

What is Biovaxys Technology Corp's Total Other Income growth rate?
Total Other Income CAGR 1Y
530%

Over the last year, the Total Other Income growth was 530%.

Back to Top